This raises the possibility of considering therapeutic BACE2 inhibition for conditions with reduced VEGFR3 signaling, such as Milroy disease, which presents with lymphedema and can be caused by a heterozygous loss of VEGFR3 function (56). This evidence concerns the gene BACE2 and lymphedema.